Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of
low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily
for potential toxicity during those 5 days. Once the patient has received 5 doses of
daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.